SCHEMBL1970586

SCHEMBL1970586

CCc1cc2c(N3CCc4ccccc4C3)nc(Cl)nc2s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 3/20 0.49
HTT P42858 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
TSHR P16473 2/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MEN1 O00255 6/20 0.43
KMT2A Q03164 6/20 0.43
GRIN2D O15399 1/20 0.43
GRIN3B O60391 1/20 0.43
CHRM1 P11229 1/20 0.43
ADRA1D P25100 1/20 0.43
ADRA1A P35348 1/20 0.43
ADRA1B P35368 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2B Q13224 1/20 0.43
GRIN2C Q14957 1/20 0.43
GRIN3A Q8TCU5 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1970675 0.84 HTR6 (0.47) HTR6HTTSMN1; SMN2MAPTNPSR1
SCHEMBL1972065 0.81 HTR6 (0.46) HTR6HTTSMN1; SMN2TSHRTP53
SCHEMBL12409637 0.80 GBA1 (0.45) HTR6MEN1KMT2AKDM4EHTR1A
SCHEMBL1966828 0.78 P2RY12 (0.53) HTR6HTTSMN1; SMN2TSHRTP53
SCHEMBL1967052 0.77 HTR6 (0.47) HTR6HTTSMN1; SMN2TSHRTP53
SCHEMBL4719406 0.76 HTR6 (0.55) HTR6HTTSMN1; SMN2TSHRTP53
SCHEMBL1968657 0.76 SMN1; SMN2 (0.42) HTR6HTTSMN1; SMN2TSHRTP53
Hydrochloric Acid SCHEMBL4720398 0.75 HTR6 (0.54) HTR6HTTSMN1; SMN2TSHRTP53
SCHEMBL1966749 0.75 P2RY12 (0.43) HTR6HTTSMN1; SMN2TSHRTP53
SCHEMBL1968096 0.74 HTR6 (0.46) HTR6HTTSMN1; SMN2TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
EP-2334689-A2 FUSED HETEROCYCLIC COMPOUND LG Life Sciences Ltd. (KR) 2011-06-22 EP disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 WO disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND F2, PF4, F11 HTR6 3031/4885HTT 2071/4885SMN1; SMN2 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.